Financial Times Names Indegene Among High-Growth Companies in AsiaPacific 2025

Indegene, a digital-first life sciences commercialization company, has been recognized among Financial Times (FT) High-Growth Companies in Asia-Pacific 2025. Recognized for the second year in a row, the ranking features companies across Asia-Pacific with the strongest revenue growth - particularly those that harness technology or adapt business models to keep expanding. This recognition is a testimony to Indegene's growth, driven by deep expertise and contextualized technology.

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products. Its client base includes the world's top 20 biopharma companies, many emerging biotech firms, and medical device companies. Indegene has about 5,000 employees worldwide, 6 operation hubs and 18 offices across North America, Europe, and Asia.

Shares of Indegene Limited was last trading in BSE at Rs. 524.30 as compared to the previous close of Rs. 514.20. The total number of shares traded during the day was 22818 in over 1267 trades.

The stock hit an intraday high of Rs. 527.00 and intraday low of 511.05. The net turnover during the day was Rs. 11952210.00.

Source : Equity Bulls

Keywords

Indegene HealthcareResearch Analytics Technology INE065X01017 FinancialTimes HighGrowthCompanies AsiaPacific2025